“david-miller” Archives

Entry Author Date Location
Dendreon Misses Wall Street’s (Already Low) Expectations for Provenge Sales 08/03/10 Seattle
Dendreon Watchers: Buckle Up for Action in First Quarterly Report With Actual Sales 08/03/10 Seattle
ZymoGenetics Melanoma Drug Passes Small Study, Gets Overshadowed by Bristol-Myers 06/05/10 Seattle
Dendreon’s Big Question: How Much Will People Pay for Provenge? 04/14/10 Seattle
Cell Therapeutics Lymphoma Drug Fails to Win FDA Approval 04/09/10 Seattle
Cell Therapeutics Looks to Pick up the Pieces After FDA Smacks Down Lymphoma Drug 03/23/10 Seattle
Dendreon Follow-Up Confirms Survival Edge, Helping Fend off Sanofi Rival 03/03/10 Seattle
Dendreon Stock Rides Roller Coaster on FDA Panel Rumor 03/02/10 Seattle
The Value of Bumping Into People in the Hall: A Lesson from the JP Morgan Healthcare Conference 01/15/10 Seattle
Omeros Accused on Eve of IPO, Seattle Genetics Trial Fails, How Much Biotechies Really Earn, & More Seattle-Area Life Sciences News 10/08/09 Seattle
DC Matters, But Biotech Can’t Neglect City Hall 10/07/09 Seattle
Dendreon Goes on Hiring Binge After Prostate Cancer Drug Boosts Survival 05/06/09 Seattle
No Devil in Details: Dendreon Data Stands Up to Scrutiny from Doctors, Investors 04/28/09 Seattle
Dendreon Clinical Trial Primer: What You Need to Know About Today’s Provenge Data 04/28/09 Seattle
Buckle Up: Dendreon Trading Halted With Prostate Cancer Results Due Tomorrow Morning 04/13/09 Seattle
Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It Prolongs Lives 04/03/09 Seattle
Biotech Analyst Runs For City Council 11/19/08 Seattle
ZymoGenetics Hands Over Atacicept Rights to Partner, Merck KGaA 09/03/08 Seattle
Dendreon Holds Its Breath, Big Provenge Clinical Trial Result Coming In October 07/31/08 Seattle
Indevus Drug Delayed by FDA Safety Questions, Shares Plummet 06/04/08 Boston
Page 2 of 2 « previous page